Skip to Content

Agilent Technologies Inc A

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Stewardship

PREMIUM

Raising Agilent’s Fair Value Estimate After Strong Q3 and Long-Term Investment Activities

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Agilent reported fiscal third-quarter results that put it on track to beat our near-term expectations. Considering that and higher cash flow expectations for the very long run based on its ongoing investment activities, we are raising our fair value estimate to $77 per share up from $69. We continue to believe a wide moat surrounds Agilent’s analytical instrument and diagnostic businesses. Also, Agilent's ongoing investments in other building blocks of medical therapies, such as expansion plans for its oligonucleotide business, add to its longer-term growth trajectory.  

Read Full Analysis

Company Profile

Business Description

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2019 sales), cross lab (36% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Just over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (31%) and China (20%) representing the largest country concentrations.

Contact
5301 Stevens Creek Boulevard
Santa Clara, CA, 95051
T +1 800 227-9770
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jul 31, 2020
Fiscal Year End Oct 31, 2020
Stock Type Classic Growth
Employees 16,300

Related